Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Two new classes of experimental drugs shown to have powerful muscle-building capabilities–selective androgen receptor modulators (SARMs) and myostatin inhibitors–have been added to the World Anti-Doping Agency’s (WADA) list of prohibited substances for 2008. Neither class of drugs is yet on the market. But the agency, an international, independent organization based in Lausanne, Switzerland, that coordinates anti-doping regulations across sports, is gearing up for future abuse by limiting use among athletes and by developing new detection methods. “We now have convincing data on those drugs and what they can do,” says Olivier Rabin, science director at WADA. “We have a duty to act as early as we can when drugs have the potential to be doping agents.”

Unlike with testosterone and other anabolic steroids, the action of SARMs and myostatin inhibitors is restricted to muscle, likely limiting side effects. That’s a very good thing for patients, but it also makes the drugs more attractive to those looking to bulk up. “I think there’s a whole new horizon for anabolic therapies, and the potential for abuse will be exceedingly high,” says William Evans, director of the Nutrition, Metabolism, and Exercise Laboratory at the University of Arkansas for Medical Sciences.

Compounds of both classes are currently in clinical trials for muscle wasting related to diseases such as cancer and muscular dystrophy. There have been no official reports of athletes using these drugs, but because there previously have been cases of athletes gaining access to compounds in clinical development, WADA officials say that they want to act early.

SARMs work similarly to testosterone but in a more targeted way. “They are effective by binding to the steroid receptor in only specific tissue, like muscle,” says Evans, who is also a scientific advisor to GTx, a company developing the drugs. “They are not steroid drugs, but they produce the anabolic effect of the steroids.” GTx, based in Memphis, TN, has shown in a clinical trial that one compound being developed for muscle wasting and bone loss can significantly boost lean muscle mass in older people.

Myostatin inhibitors work through a fundamentally different mechanism. They block myostatin, a naturally occurring protein in the body that stops growth of skeletal muscle. Cattle, sheep, dogs, and, in one confirmed case, a human with mutations in this gene are extremely muscular. (See “Mimicking the Massively Muscular.”)

Scientists have developed antibodies to myostatin and other molecules that can boost lean muscle mass in animals by as much as 60 percent. It’s not yet clear how well myostatin inhibitors will work in humans. Clinical studies of two myostatin inhibitors are now under way for muscular dystrophy and other muscle-wasting diseases.

WADA is developing detection methods for both SARMs and myostatin inhibitors, although the agency declined to say how far along those tests are. “In fairness to athletes who stay clean, we don’t say when detection tools are available,” says Rabin. “We say when we detect the first athletes using the drugs.”

17 comments. Share your thoughts »

Credit: AP Images/Doug Mills

Tagged: Biomedicine, cancer, drugs, medicine, sports, muscular dystrophy

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me